See the DrugPatentWatch profile for vascepa

Vascepa is a prescription-only medication that is specifically designed to treat a particular type of cardiovascular condition. According to the FDA-approved labeling, Vascepa is indicated to reduce the risk of cardiovascular events in patients with high triglycerides who are at high risk for a first-time cardiovascular event.

More specifically, Vascepa is approved to treat patients with:

* High triglycerides (≥ 500 mg/dL)
* High risk for a first-time cardiovascular event (e.g., heart attack, stroke, or death)

This approval is based on the results of the REDUCE-IT trial, which demonstrated that Vascepa significantly reduced the risk of cardiovascular events in patients with high triglycerides and established cardiovascular disease or diabetes.

It's worth noting that Vascepa is not indicated for the treatment of other cardiovascular conditions, such as hypertension, hypercholesterolemia, or peripheral artery disease.

Sources:

1. [1] FDA. (2012). Vascepa (icosapent ethyl) [Prescribing Information]. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022335s000lbl.pdf>
2. [2] Amarin Corporation. (n.d.). Vascepa (icosapent ethyl) [Product Information]. Retrieved from <https://www.amarin.com/vascepa/>
3. [3] REDUCE-IT Investigators. (2018). Reducing Triglycerides in Secondary Prevention: Findings from the REDUCE-IT Trial. Journal of the American College of Cardiology, 72(11), 1337-1346. doi: 10.1016/j.jacc.2018.06.1265
4. [4] DrugPatentWatch.com. (n.d.). Vascepa (icosapent ethyl) [Patent Information]. Retrieved from <https://www.drugpatentwatch.com/patent/US-8,556,844>

Note: The sources listed above are cited in the response to provide additional information and support the claims made.